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Computer-aided molecular modelling of the endothclin (ET-A) receptor antagonists, BQ-123 and BE-18257B. shows that hey have very similar 
3D structures. Parts of their 3D structures are also shown to match closely with that reported for residues 6-8 in endothelind. On the basis of 
these similarities (and with supporting evidence from literature data on endothelin structure-activity relationships) a structural determinant is 
proposed for ET-A receptor binding, and novel designs of peptide are suggested for providing more potent and selective ET-A receptor antagonists. 
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1. INTRODUCTION 
The endothelins are a novel family of vasoconstrictor 
peptides, each consisting of 21 amino acid residues with 
two intra-chain disulphide linkages (see Fig. 1). The first 
member of the family identified, endothelin-I (ET-I), 
was isolated from the cultured supernatant of porcine 
aortic endothelial cells [1]. Subsequent screening of a 
genomie DNA library (using a synthetic oligonucleotide 
probe encoding a portion of the ET-I sequence) led to 
the discovery of the other two members of the family, 
endothelin-2 (ET-2, also known as vasoactive intestinal 
contractor) and endothelin-3 (ET-3) [2]. ET-I was first 
shown to have potent vasoconstrictor activity [1] but 
was later also shown to have contractile activity on 
various non-vascular smooth musclesar~d some activity 
in the CNS [3]. 
Binding studies of labelled ET-1 have shown a wide 
distribution of ET-specific binding sites, not only in the 
vascular system but also in the kidneys, lungs, adrenal 
glands and neurons [4]. The sequences for five different 
ET receptors have so far been determined and these are 
divided into sub-types A and B. The ET-A receptors are 
distinguished by a higher affinity for ET-I and ET-2 
than ET-3 [5-7], and the ET-B receptors have an equal 
affinity for all three endothelins [8-10]. A further recep- 
tor with a higher affinity for ET-3 than ET-1 has been 
found in the anterior pituitary cells but its sequence has 
not yet been determined [11]. 
It has been suggested that ET and ET receptors have 
vital functions associated with haemodynamic regula- 
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tion and/or modulation of the cardiovascular system, 
but the details of their physiological and pathological 
roles are still unclear (see [12] for a recent review). In 
order to gain further understanding of these phenom- 
ena, it is thus essential to identify specific ET-reeeptor 
antagonists. 
Although various ET-I analogues have been shown 
to have some antagonistic activity [13-14] none of the 
compounds so far considered have sufficiently high re- 
ceptor specificity and/or affinity. However, lhara et el. 
have recently reported the discovery era  natural antag- 
onist, BE-18257B [15], and its chemical modification to 
a more potent antagonist, BQ-123 [16]. Both of these 
antagonists are specific to ET-A receptors and are cyclic 
pentapeptides with alternating D- and L-amino acids 
(see Fig. 1). 
In the following study, the 3D structure of  these two 
antagonists are predicted, and the resulting models are 
then compared against the various solution structures 
for ET-1 that have been determined by means of 2D 
NMR and distance geometry calculations [17-19]. On 
the basis of these analyses a possible structural determi- 
nant of ET-A receptor binding is identified, and novel 
peptide designs are proposed for consideration as syn- 
thetic ET-A receptor antagonists. 
2. MATERIALS AND METHODS 
2.1. Modelling of the ET atttagonlsts 
Ranges of possible conformers for the two ET antagonists. BE- 
18257B and BQ-123, were generated using a combination fconfor- 
mational search, claster analysis and energy minimization. The vari- 
ous s'.ages involved in the model building were as follows: 
(1) 100 conformers were first generated for the cyclic main chains 
of the two antagonists u ing the program RAMBLE [20]. The main 
chaintorsion angles were constrained in the ranges: 
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@ = -180 ° tO -30 ° 
@=-80 ~ to -400 
@= 30 ° to .180 °
= -90" to 180 ° (for L-amino acids 
except Pro) 
= -90 ° to 180 ° (for L-pro) 
= -180 ° to 900 (for o-amino acids) 
All peptide bonds were fixed as trans planar, and bond lengths and 
bond angles were taken from Creighton [21]. The cyclization of the 
linearly generated structures was accomplished by constraining the 
distance between the N and th~ C' atoms of Tr# and Leo ~ in the range 
I-3 A, with the peptide bond torsion angles and bond angles formed 
on ring closure constrained to their ideal values ±20 °. 
(it) Cluster analyses of the resulting main chains were then per- 
formed to eliminate redundant structures [20]. This gave 10 unique 
main chain conformers for BE-18257B, and 17 for BQ-123. 
(iii) After addition of hydrogen atoms, each of these cyclo-penta- 
alanyl peptides was then energy minimized (using the COSMIC force 
field [22], but with neglect of Coulombic interactions) essentially just 
to regularize the geometry at the ring closure point, 
(iv) Next, the appropriate amino acid side chains (and a corrected 
set of hydrogen atoms) were added to each of the antagonist main 
chain structures, using the program GLUE [20]. For each residue a 
range of possible side chain conformations was considered. The pre- 
ferred conformations for the side chains of the L-amino acids were 
taken from Perkins [23], and those of the t~.amino acids were con- 
structed according to the rule: preferred g angle lbr o-amino acid = 
-preferredx angle for L-amino acid [24]. In total there were 2,250 full 
atom models considered for BE-18257B, and 3,060 for BQ-123. 
(v)  Partial atomic charges for these two sets of structures were 
determined using CNDO/2, and their potential energies calculated 
u,ing COSMIC [22]. 
(vi) For each antagonist the 200 conformers of lowest initial poten- 
tial energy were subjected to 100 c2¢eles of Newton Raphson/Simplcx 
minimization using the full COSMIC force field. The two sets of 50 
conformers of lowest final potential energy were then employed in the 
subsequent analyses. 
2,2 Modelling of ET.l residues 3-11 
In view of the similarities between the ET-I/ET-2 sequences Leu"- 
MetLAsp~ffrp°-LeuLAsp ~ and the sequences Leu-n-Trp-t~-Glu in BE- 
1825715 and Leu.t~-Trp-mAsp in BQ-123, it was decided to construct 
models of the ET.I loop encompassing residues 3-11, in order to 
investigate its possible structural similarity with the antagonists. The 
models of the loop were built using RAMBLE [20], employing the @/~ 
angles given by Endo et el, [17] and Krystek et el. [18]; thezt and 2": 
angles for Cys ~ and Cy# t w~re kept variable, and the separation of 
their S7 atoms was constrained in the range of 1-3 A in order to allow 
disulphide formation. Regularization f the geometry of the structures 
was carried out as de3cribcd in (iii) above, 
3. RESULTS 
For each of the 50 low energy structures for BQ-123, 
the main chain torsion angles were compared against 
those determined from NMR studies of this peptide in 
aqueous acetonitrile [25]. In all cases the torsion angles 
compare very favourably, with mean deviations typi- 
cally of the order of +_30 °. The match with the NMR 
structure also extends to the side chain conformations, 
and many of the low energy conformers have very sim- 
ilar gt angles for Trp t, (g-), Asp 2 (t) and VaP (g-). 
(These similarities give encouragement that the mod- 
elling procedures adopted provide an adequate descrip- 
tion for the peptide's conformation i  solution, but are 
not entirely unexpected: the peptide cycle is highly con- 
strained since it involves only 5 amino acid residues, and 
r '.~ 
ET-I Oy~ Set C¢# Scr Set Lea Met Asp L~ Olu C~ Val T~r Ph¢ C~ 14h Lea Asp lle eTrp 
El'..* Cy~ ~r  Cyz Scr 5¢r Trp Lea A~p L),~ Ol. O# Val 'r,/r Phe O# liia l.~u Asp 11¢ lie Trp 
L~r.3 t2~ Thr O~, Ph¢ Thr'l~t L~ Asp L~s Glu ~ Val T~,r Tyr Q~ Ilia I.~u ASp lie ll¢'rrp 
BE-ISL~?B ¢/clo -(D.T~.D.O ia,~Ma.allo.n.lle.Leu) 
BO.l~ o/do -( O.Trl~n.Aap.Pro-O.VaI.Le a) 
Fig, I. Amino acid sequences of pgptides fi'om the endothelin thmily 
[12] and the two ET.A receptor antagonists, BE-18257B [15] and 
BQ-123 [16]. 
is further estricted by the alternatiug pattern of L- and 
o-amino acids.) 
In virtually all of the low energy conformers for BQ- 
123 (see for example Fig. 2a), the peptide cycle is ap- 
proximately planar, with a ~, turn stabilized by hydro- 
gen bonding between the VaP NH and Asp 2 CO groups. 
In contrast with the structures derived from preliminary 
NMR data [25], but wholly consistent with more recent 
findings [2@ there is no type IIf l  turn observed over 
residues VaP-Leu~-Trp t-Asps-; insteadthe CO groups of 
Leus and Trp t are oriented away from the peptide cycle, 
directed out into solvent. 
For BE-18257B, the low energy structures match 
closely with those obtained for BQ-123 (see Fig. 2b); 
there is a root-mean-square difference (rmsd) of the 
order of 0.5-2.5 A for least squares fits over all the main 
chain and Cfl atoms, and very similar preferences for 
the Xt angles of all residues except Pro~/Ala ~. More sig- 
nificantly, however, the two sets of structures display a 
particularly close match over the 10 atoms: Leu ~ (C/J, 
C~t, C', O), Trp L (N, Ca, C', O) and Glue/Asp a(N, C~t), 
with the majority of the pairwise comparisons giving an 
rmsd <0.5 A. 
Comparisons of these parts of the two antagonists 
against he corresponding 10 atoms in residues 6-8 in 
ET-1 showed encouraging similarities (see Fig. 2c). The 
lowest rmsd's obtained for the least squares fits to the 
models from Endo et al. [17] were 0.27 A for BQ-123 
and 0.28/~ for BE-18257B. The corresponding rmsd's 
for fits to the models from Krystek et al. [!8] were 1.0 
A and 0.83 A. Since there is a better fit between the two 
antagonists and the solution structure of ET in DMSO. 
it is tentatively suggested that this conformation of ET 
more closely resembles that required for ET-receptor 
activity. Note also therefore, that it is this model that 
appears most consistent with the data from fluorescence 
energy transfer experiments [27]. 
4. DISCUSSION • AND CONCLUSIONS 
From the molecular modelling studies performed 
here it is apparent that the main chain conformations 
and general side chain dispositions for the residues 
LeuS--->Asp 2 in BQ-123 and Lea~--cGIu "~in BE-18257B 
are very similar to those reported ,,,, f". . . . .  ,,,o,,,,,,.~-1 . . .  Leo6 .__> 
Asp ~ in ET-I. Given the similarity in the sequences of 
these parts of the two antagonists and ET-I, we there- 
fore propose that the loop residues 6-8 in ET-I are 
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Fig. 2. Stereo-views showing (a) a representative model of the 3D structur~ of BQ-123. (b) a representative model of the 3D structure of BE-18257B. 
and (e) the superposition of residues LeuS.D-Trpt.D.Asp" in BQ-123. residues LeuO-MetT-Asp" in ET-I. and residues LeuS-n-TrpJ-~Glu-" in 
BE-18257B. In (a) and (b) the antagonists structures are viewed with the N --4 C-terminal sense running anti-clockwise. In (c) the ET-ioop is 
presented in bold. with the N- and C-termini labelled and only the main-chain and C~ atoms hown. 
involved in the binding of this peptide to the ET-A 
receptor, and that BQ-123 and BE-18257B achieve their 
antagonist activities by mimicking the structure of this 
loop. 
In view of the sequence similarity between the two 
antagonists and the ET C-terminus, it is also possible 
that the antagonists might work by mimicking the ET 
residues Leu 17 ---> Trp 2~. It has been shown by Maggi et 
al. [28], however, that although ET (16-21) exhibits full 
agonist activity at the ET-13 receptor, it is completely 
devoid of both agonist and antagonist activity at the 
ET-A receptor. Since BQ-123 and BE-18257B are spe* 
cific for the ET-A receptor, it seems improbable, there- 
fore, that they mimick this part of the peptide. Indeed, 
several groups of workers [29-32] have now provided 
evidence to show that it is the tertiary structure of ET 
(in particular, the loop dictated by the two disulphide 
bridges) that represents the most critical factor in its 
recognition at the ET-A receptor. Specifically, it is 
noted that the disulphide-reduced ET [29], fully Cys- 
protected ET [30] and [Ala ~, Ala a, Ala j J, Ala Is] ET [31]~ 
as well as the ET derivative formed by cleaving at Lys 9 
with lysyl endopeptidase [29], all have greatly reduced 
potency by comparison with native ET-1. (It is surpris- 
ing to observe, however, that there is no apparent loss 
in receptor binding For ET cleaved at Met 7 by cyanogen 
bromide treatment [33], but the full effects of this mod- 
ification remain to be determined.) 
From the least squares uperpositions of the two an- 
tagonist structures and the ET-1 loop residues.• it is 
postulated that the key features on the ET.A rcceplor 
surface involved in agonist/antagonist recognition will 
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include: two hydrogen bond donor sites, two fairly non- 
specific hydrophobic binding sites, and a third binding 
site bearing a positive charge. The first hydrophobic 
binding site must be large enough to accommodate Trp 
(as in ET-2), but will also readily bind the smaller Leu 
side chain (as in the antagonists and ET-I). The second 
hydrophobic binding site will also accommodate Trp 
(as in the two antagonists), but equally well accommo- 
dates Nle [34], Met (as in ET-1) or Leu (as in ET-2). 
Since BQ-123 exhibits a significantly higher affinity for 
the receptor by comparison with either BE-18257B or 
[GIu~-]-BQ-123 [16], it is apparent that the cationic bind- 
ing site on the receptor preferentially binds the shorter 
side chain, Asp, rather than the longer side chain, Glu. 
The two key hydrogen bond donor groups on the recep- 
tor will hydrogen bond to the CO groups of •residues 6 
and 7 in ET.I and ET-2; or those of Leu 5 and Trp t in 
the antagonists. 
Once again these hypotheses are consistent with ex- 
perimental observations. An t.-Ala scan of the ET-1 
sequence [35] shows that: (i) the Ale 6 analogue binds 
just as well as ET.I to h-vsm ceils, and shows much the 
same contractile activity in rabbit vena cava; (it) the 
Ala 7 analogue shows no diminution in contractile activ- 
ity, but has a 3.5x higher receptor affinity; (iii) the Ale s 
analogue shows a 100-fold reduction in contractile ac- 
tivity, but binds more or less as well as ET-1. In addi- 
tion, it is noted that the substitutions Leu e -., Gly 6 and 
Met 7 ~ Met(O) 7 lead to ET derivatives with 70-75% 
activity, whereas the substitution Asp * ~ Asn s gives a 
peptide with <1% activity [31]. These results would thus 
appear to support he view that the binding sites on the 
ET-A receptor for the ET residues, 6 and 7, are rela- 
tively non-specific and hydrophobie, whereas the site 
for accommodating residue 8 requires a negatively 
charged carboxylate group. 
From a scan o f  the ET-1 sequence using D-amino 
acids [36], it is noted that the o.Leu 6 and D-Met 7 ana- 
logues have similar affinities and activities to ET-1, and 
that the D-Asp s analogue xhibits a 33-fold reduction in 
binding and a 100-fold reduction in activity. Hence, the 
orientations (and by implication, therefore, the sizes) of 
the side chains at positions 6 and 7 in ET-I would not 
seem to be stringently dictated by their ET-A receptor • 
binding sites. In contrast, however, the conformation of 
residue 8 appears to be Critical, not only for receptor 
binding, but also for biological activity. 
In conclusion, we note that novel designs of ET-1 
peptide antagonist with improved ET-A receptor affin- 
ity and selectivity may be produced using a minimum 
of 3 residues: the first of these will ideally be Leu (or 
possibly Nle, el. [34]), the second Ala, and the third, 
• Asp. Also, since the conformation of the molecule must 
be arranged so that the two peptide CO groups are 
available for intermolecular hydrogen bonding, there 
must be some constraints employed to ensure that the 
structure forms a loop. • It is instructive • therefore to see 
that Fujisawa have recently proceeded to in rive testing 
of an ET-I antagonist which is a pseudo-tripeptide with 
Leu and methyl-Trp side chains, a C-terminal carboxyl, 
and N- and C-terminal hydrophobic groups to stabilize 
an intramolecular turn [37]. 
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